3 completed, 1 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow CicloMed LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia Fosciclopirox, Fosciclopirox + Cytarabine - Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | CicloMed LLC | 18 | 2021-08-27 | 2024-02-12 |
| Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors CPX-POM - Bladder Cancer | Phase 2 | Completed | CicloMed LLC | 12 | 2020-11-25 | 2024-06-18 |
| Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors CPX-POM - Advanced Solid Tumor | Phase 1 | Completed | CicloMed LLC | 9 | 2019-05-19 | 2025-03-03 |
| Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors CPX-POM - 30 mg/m^2, CPX-POM - 60 mg/m^2, CPX-POM - 120 mg/m^2 - Advanced Solid Tumors | Phase 1 | Completed | CicloMed LLC | 19 | 2018-01-15 | 2021-12-03 |
Leukemia, Myeloid, Acute (1) · Urinary Bladder Neoplasms (1)
Cytarabine (1)
United States (4)